Pricing and contract structure
WellSky Home Health is sold by custom quote — you learn your price through a sales process, and third-party directories cite figures from roughly $50 per user per month with small-agency totals commonly in the hundreds to low thousands monthly (as of June 2026). Copergrine publishes its price: $229 per provider seat per month for the first six months, then $380, with admin, billing, QA, and front-desk staff free.
Because WellSky quotes per agency, the real comparison is your quote against Copergrine's published page. On Copergrine, only billing clinicians consume seats — intake coordinators, QA reviewers, schedulers, and billers ride free under the seat cap — so the per-seat number maps directly to revenue-producing staff.
Neither platform offers a meaningful free tier; Copergrine offers a 14-day trial so your team can run real workflows before committing.
Clinician documentation experience
WellSky's point-of-care charting is genuinely liked — reviewers consistently say it's easy to learn and lets clinicians spend more time on patient care. The recurring complaints are operational: no autosave, a 10-minute inactivity logout, and lost work when a session drops mid-visit. Copergrine attacks the same problem from the other direction — the AI scribe and auto-fill templates draft most of the note before the clinician starts typing.
Copergrine's discipline-specific scribe drafts PT, OT, SLP, RN, and HHA visit notes, and auto-fill clinical templates carry forward prior data into discrete coded fields — less typing per visit, and the structured data stays defensible for ADRs and surveys. The 485 Plan of Care is AI-drafted from the assessment, then reviewed and signed by the clinician.
For field visits in connectivity dead zones, Copergrine's EVV captures the visit offline with geofence verification and syncs when the device reconnects — the visit-time record doesn't depend on a live connection at the doorstep.
OASIS-E, PDGM, and regulatory compliance
Both platforms track CMS requirements, and WellSky earns credit from reviewers for shipping regulatory updates that keep claims accurate. Copergrine goes a step further on enforcement: OASIS-E validation gates physically block an incomplete assessment from being submitted, so compliance doesn't depend on a QA reviewer catching the gap downstream.
Some WellSky reviewers report glitches in the OASIS and insurance sections that force workarounds — an honest reminder that breadth and tenure don't immunize a platform from rough edges. On Copergrine, PDGM grouping, HIPPS scoring, and 30-day payment periods are computed inside the same system that holds the chart, so the claim and the documentation can never silently disagree.
Billing and denial prevention
WellSky's automated billing and scheduling are among its most-praised features — they reduce manual error and speed reimbursement. Copergrine's differentiator is what happens before the claim exists: a billing-holds engine that refuses to release any claim while OASIS is incomplete, the face-to-face is missing, the certification is unsigned, an authorization has expired, or QA returned the chart.
That structural gate is what 'zero silent denials' means: an incomplete claim cannot leave the building, so denials don't surface as six-week-old surprises in your accounts receivable. Holds are visible in QA workqueues and on the agency Command Center — census, visits due, documentation pending, holds, and capacity in one dashboard — the day they form.
Support and onboarding
WellSky reviewers describe a fast-to-learn product but a slow-to-reach support organization — long response times, poor follow-up, and thin onboarding are recurring themes on Capterra and TrustRadius. Copergrine includes direct support and is built to take an agency live in days.
Copergrine also moves guidance into the product itself: validation gates explain what's missing, the holds queue says why a claim is parked, and the Command Center makes the day's bottlenecks visible without a support ticket. When you do need a human, support is part of the subscription, not an upsell tier.
